Portale Epatite e malattie del fegato
Sito Epatite B
Sito Steatosi
Sito Cirrosi
Sito Tumori
Sito Trapianti
Nuovi Farmaci
Malattie autoimmuni

Studi scientifici principali



    1. Scheda tecnica Sovaldi (riferimenti su tutti i paragrafi del documento)

    2. Indicazioni terapeutiche approvate da EMA

    3. Eric Lawitz,1 Fred F. Poordad et al, APASL 2014

    4. Michael P. Curry, Xavier Forns et al, AASLD 2013

    5. Didier Samuel, Michael Charlton, Edward Gane et al. EASL 2104
      Sofosbuvir and Ribavirin for the Treatment of Recurrent Hepatitis C Infection After Liver Transplantation: Results of a Prospective, Multicenter Study

    6. Nezam Afdhal, Gregory Everson, Jose Luis Calleja et al, EASL 2014
      Sofosbuvir and Ribavirin for the Treatment of Chronic HCV With Cirrhosis and Portal Hypertension With and Without Decompensation: Early Virologic Response and Safety

    7. Mark S Sulkowski, Ira M Jacobson, Reem Ghalib,et al., EASL 2014
      Once-daily simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in HCV genotype-1 prior null responders with METAVIR F0-2: COSMOS study subgroup analysis

    8. Eric Lawitz, Reem Ghalib, Maribel Rodriguez-Torres, et al, EASL 2014
      Simeprevir plus sofosbuvir with/without ribavirin in HCV genotype-1 prior null-responder/treatment-naïve patients (COSMOS study): primary endpoint (SVR12) results in patients with METAVIR F3-4 (Cohort 2)


Vuoi ricevere aggiornamenti su questo argomento? Iscriviti alla Newsletter!